Skip to main content
Terug
Watch Compare

AVENUE THERAPEUTICS, INC.

Datakwaliteit: 100%
ATXI
OTC Manufacturing Chemicals
€ 0,45
▲ € 0,10 (28,57%)
Marktkapitalisatie: 1,48 M
Prijs
€ 0,45
Marktkapitalisatie
1,48 M
Dagbereik
€ 0,45 — € 0,45
52-Weeksbereik
€ 0,15 — € 0,97
Volume
2.937
Openen € 0,45
50D / 200D Gem.
€ 0,24
91,00% above
50D / 200D Gem.
€ 0,54
16,85% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -1,83 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-76,40%
Onder sectorgemiddelde (-53,41%)
ROIC-94,86%
Net Margin-207,19%
Op. Margin-219,59%

Veiligheid

Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A

Waardering

PE (TTM)
-0,51
Boven sectorgemiddelde (-1,48)
P/B Ratio0,42
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,5 -1,5
P/B 0,4 1,6
ROE % -76,4 -53,4
Net Margin % -207,2 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,40 M Net Income (TTM) -2,91 M
ROE -76,40% ROA -73,78%
Gross Margin N/A Operating Margin -219,59%
Net Margin -207,19% Free Cash Flow (TTM) -1,83 M
ROIC -94,86% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio N/A
Interest Coverage N/A Asset Turnover 0,36
Working Capital N/A Tangible Book Value 3,56 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,51 Forward P/E N/A
P/B Ratio 0,42 P/S Ratio 1,06
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -123,64%
Market Cap 1,48 M Enterprise Value -2,23 M
Per Share
EPS (Diluted TTM) N/A Revenue / Share 0,43
FCF / Share -0,56 OCF / Share -0,56
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 63,01%
SBC-Adj. FCF -2,69 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,40 M — — — —
Net Income -2,91 M -11,70 M -10,49 M -3,55 M -3,73 M
EPS (Diluted) — — — — -0,22
Gross Profit — — — — —
Operating Income -3,08 M -11,28 M -14,54 M -8,04 M -3,74 M
EBITDA — — — — —
R&D Expenses 1,04 M 6,65 M 6,13 M 2,70 M 1,25 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — —
Income Tax 2.000,0 0,0 0,0 — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2,93 M 2,67 M 1,85 M 6,85 M 3,96 M
Total Liabilities 1,10 M 816.000,0 1,20 M 3,58 M 509.000,0
Shareholders' Equity 1,83 M 2,80 M 1,58 M 3,91 M 3,45 M
Total Debt — — — — —
Cash & Equivalents 2,86 M 2,59 M 1,78 M 6,71 M 3,76 M
Current Assets — — — — 3,96 M
Current Liabilities 1,10 M 816.000,0 1,20 M 3,58 M 509.000,0